Solvonis Therapeutics (LON:SVNS – Get Free Report) released its earnings results on Wednesday. The company reported GBX (0.02) EPS for the quarter, Digital Look Earnings reports.
Solvonis Therapeutics Price Performance
SVNS stock opened at GBX 0.10 on Friday. Solvonis Therapeutics has a 1-year low of GBX 0.10 and a 1-year high of GBX 0.40. The firm has a fifty day moving average price of GBX 0.13 and a two-hundred day moving average price of GBX 0.19. The firm has a market cap of £7.66 million and a price-to-earnings ratio of -0.81.
About Solvonis Therapeutics
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company headquartered in the United Kingdom. The company is developing a proprietary synthetic exosome platform designed to enhance the targeted delivery of therapeutic compounds. By engineering nanoscale vesicles that mimic natural exosomes, Solvonis aims to improve tissue selectivity, increase payload stability and enable efficient transport of small molecules, peptides and nucleic acids across biological barriers.
The company’s lead programs focus on oncology and central nervous system disorders, where delivery challenges have historically limited the efficacy of novel therapeutics.
Recommended Stories
- Five stocks we like better than Solvonis Therapeutics
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
Receive News & Ratings for Solvonis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solvonis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
